Gri Bio Q1 FY26 net loss narrows to $2 million from year-ago quarter

• Gri Bio reported a net loss of USD 2 million for quarter ended March 31, 2026, narrowing from USD 3.05 million year earlier.
• Operating loss improved to USD 2 million from USD 3.05 million as operating expenses fell to USD 2 million from USD 3.05 million.
• R&D expense dropped to USD 361,000 from USD 1.64 million due to completion of GRI-0621 Phase 2a trial, while G&A rose to USD 1.64 million from USD 1.41 million on higher public company costs.
• Cash totaled USD 11 million at March 31, 2026; operating cash outflow widened to USD 3.69 million from USD 1.74 million, while financing cash inflow was USD 6.5 million driven by USD 6.8 million of ATM proceeds.
• GRI-0621 Phase 2a IPF study met primary endpoint of safety and tolerability with no treatment-related serious adverse events; company said existing cash should fund operations into second quarter of 2027 but it would need substantial additional capital to complete a Phase 2b trial.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gri Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001824293-26-000044), on May 13, 2026, and is solely responsible for the information contained therein.